The strength training sweet spot for a longer life: how many minutes a week are enough

It has taken time for the link between strength training and longevity to be put on solid scientific ground. While the cardiovascular benefits of aerobic exercise have been well documented for decades, the impact of weight work on mortality is a relatively new area of research. The new meta-analysis reported by Science Daily identifies a "sweet spot" for strength training — the peak of the benefit curve.
The key finding is this: people who do about 30 to 60 minutes of strength training a week lower their overall risk of death by roughly 10 to 17 per cent compared with those who do none. The benefit also shows up separately for deaths from cardiovascular disease and from cancer. Doing less is still helpful; doing significantly more, beyond a point, brings diminishing returns on added benefit.
Why a "sweet spot"? Longer and more frequent training has no obvious harm, but the mortality curve flattens after a certain weekly volume and even shows a mild upward turn. Scientists interpret the shape with two explanations: very high training volume increases injury risk, and the time spent outside training — sleep, nutrition, social life — itself shapes health.
What does the right programme look like? The clinical message of the study is to train two to three days a week. For each exercise, do one to three sets of eight to twelve repetitions. Compound movements that work large muscle groups — squat, deadlift, bench press, pull-up and overhead press — should come first. No particular machine is required; bodyweight exercises, a home resistance band or a basic gym set-up will do.
What are the biological mechanisms by which strength training influences lifespan? Studies show that increased strength reduces insulin resistance, improves glucose tolerance, raises mitochondrial number and efficiency, lowers the risk of sarcopenia — the age-related loss of muscle mass — and prevents fall-related injuries. Each of these alone produces a meaningful effect on mortality.
The recommendations differ by age. From 18 to 40, building baseline muscle mass matters; from 40 to 60, preserving muscle mass takes priority; over 60, fall risk and bone density become the main targets. As age advances, reducing the number of repetitions per set and tightening control of the load points to a safer programme.
For women, strength training is especially valuable. The drop in oestrogen after menopause directly affects bone density; strength training is shown to be the most powerful lifestyle intervention slowing that loss. The study notes that women's average frequency of strength training is lower than men's and that closing the gap could deliver a public-health gain.
The combined effect — strength plus aerobic — produces more benefit than strength training alone. The study finds that combining 150 minutes of moderate-intensity aerobic exercise per week with 30 to 60 minutes of strength training can lower the risk of death by 35 to 40 per cent. That is strong quantitative evidence that backs existing WHO and US CDC recommendations.
The first six weeks of a programme matter in practice. For beginners, the advice is to work with light weights to learn form in the first two weeks, raise the load gradually in the next two, and apply progressive overload within a target repetition range in the final two. Keeping a training log of what was lifted gives an objective view of progress.
The practical take-away for Vesper readers: train two to three days a week, with each session 20 to 30 minutes targeting large muscle groups. A gym membership is not required; anyone with a medical history or chronic condition should consult their doctor before starting. What matters is starting and sticking with it — the benefit curve reaches its peak at a volume that is highly achievable.
Read next

Glucosamine and Alzheimer's: what a popular joint supplement may mean for the brain
New research suggests that glucosamine, a widely used joint supplement, may speed up the progression of Alzheimer's disease in patients who already have dementia. Science Daily explains what the findings mean for all users and who falls into the at-risk group.

Two children die of measles in England: the vaccination-rate question behind 100 new cases
The deaths of two children from measles in England and the reporting of 100 new cases in recent weeks have pushed the country's falling MMR vaccination coverage into the public spotlight. Guardian Health reported the geographic distribution of cases and the urgent recommendations from public-health authorities.

What is synthetic lethality? The principle that is rekindling cancer drug research
Synthetic lethality is the principle by which inhibiting a second target proves fatal to a cancer cell when a first gene has been lost. STAT News reports on how the principle is fuelling a new wave of biotech mergers and acquisitions and which companies are appearing on investors' radars.

Meningitis B vaccine: why a million young people in the UK are being offered the shot
England will offer the meningitis B vaccine to around a million young people, including school leavers and university students. BBC Health set out why the programme is being launched, which age group is most at risk and what level of protection the shot provides.

Lupus and CAR-T cell therapy: how an immune reset is putting patients into remission
Lupus is a chronic disease in which the immune system attacks the body's own tissue. A new cell therapy reprograms patients' own T-cells and, in some cases, has produced drug-free remission; BBC Health reported the findings of a new UK trial.
